Bayyanar Cututtuka na COVID-19

Bayyanar Cututtuka na COVID-19


Bayyanar cututtuka na COVID-19 Alamomi ne ko alamun cutar Coronavirus 2019 da ke faruwa a cikin fata. Cibiyar Nazarin Dermatology ta Amurka ta ba da rahoton cewa raunukan fata irin su morbilliform (kyanda-kamar rashes, 22%), pernio (lalacewar capillary, 18%), urticaria (amya, 16%), macular erythema (rash mai launin fure, 13%)., vesicular purpura (dini mai launin ruwan kasa, 11%), papulosquamous purpura (dislouration with sikelin. 9.9%) da retiform purpura (katsewar jini da ischemia na ƙasa, 6.4%) ana ganin su a cikin mutanen da ke da COVID-19.[1][2][3] Kwayoyin cututtuka irin na Pernio sun fi kowa a cikin ƙananan cututtuka yayin da ake ganin purpura na retiform kawai a cikin marasa lafiya marasa lafiya.[1] Manyan dermatologic alamu gano a cikin mutane tare da COVID-19 ne urticarial rash, confluent erythematous / morbilliform rash, papulovesicular exanthem, chilbain -like acral juna, livedo reticularis da purpuric "vasculitic" kwaikwaya.[4] Chilblains da Multisystem kumburi ciwo a cikin yara suma bayyanar cututtuka ne na COVID-19.[5]

Amsoshin rigakafi na hyperactive a cikin marasa lafiya na Covid-19 na iya ba da gudummawa ga ƙaddamar da " guguwar cytokine " (musamman, IL-6 ); waɗannan cytokines na iya shiga cikin fata kuma suna haifar da ƙwayoyin dendritic dermal, lymphocytes, macrophages, ƙwayoyin mast, da neutrophils, kuma zasu iya taimakawa wajen ci gaba da raunuka irin su maculopapular rash . An kwatanta wannan wakilcin raunin da ya faru a baya a cikin cututtuka da ke da amsawar rigakafi da yawa da kuma sakin cytokine mai yawa (misali, lupus erythematosus na tsarin jiki, cutar ta manya, da ciwon maganin antiphospholipid ).[6]

Urticarial kurji

[gyara sashe | gyara masomin]

Ana ganin kurjin urticarial (amya) a cikin ƙwayoyin cuta da ƙwayoyin cuta da yawa, don haka COVID-19 ba banda. Wadannan rashes an fi samun su a cikin akwati da kuma gaɓoɓin gaɓoɓinsu, in mun gwada da ɓata guraben acral. Corticosteroids na tsari zaɓi ne na warkewa don kurjin urticarial wanda COVID-19 ya haifar.[4]

Raunin erythematous mai rikitarwa

[gyara sashe | gyara masomin]

Rashes na erythematous (jajayen da ke haifar da karuwar jini ta hanyar capillaries na fata) da ake gani a cikin COVID-19 galibi suna kan gangar jikin da gabobin jiki, kuma suna da alaƙa da ƙaiƙayi.[4] Misalan da ƙwayoyin cuta ke haifar da banda COVID-19 da halayen ƙwayoyi yakamata a ɗauki su azaman ganewar asali na bambance bambancen a yanayin kurjin kurji.[4]

Livedo reticularis

[gyara sashe | gyara masomin]

Livedo reticularis yana nufin raguwar kwararar jini, wanda ke haifar da desaturation na jini da launin shuɗi na fata. Ana iya ganin irin wannan nau'in fata na fata a cikin vasoconstriction mai sanyi kamar yadda aka gani a cikin polycythemia ko wasu abubuwan da ke haifar da lalatawar jini.[4]

Histopathological halaye

[gyara sashe | gyara masomin]

Daga hangen nesa na tarihi (microscopic anatomy), an gane fasali da yawa na raunin maculopapular. Raunin Maculopapular yana nuna dermatitis na perivascular tare da infiltrate na lymphocytic da tasoshin ruwa a cikin papillary da tsakiyar dermis tare da neutrophils, eosinophils, da tarkace na nukiliya. Epidermis bayyana tarwatsa foci na hydropic canje-canje, tare da m acanthosis, subcorneal pustules, spongiosis kadan, Basal cell vacuolation, da kuma foci na parakeratosis.[6] An lura da tsarin lichenoid tare da kasancewar eosinophils akan biopsy na raunukan fata a wasu marasa lafiya.[7]

Kara karantawa

[gyara sashe | gyara masomin]
  • Seirafianpour F, Sodagar S, Pour Mohammad A, Panahi P, Mozafarpoor S, Almasi S, Goodarzi A (November 2020). "Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review". review. Dermatologic Therapy. 33 (6): e13986. doi:10.1111/dth.13986. PMC 7362033. PMID 32639077.

Manazarta

[gyara sashe | gyara masomin]
  1. ↑ 1.0 1.1 Freeman EE, McMahon DE, Lipoff JB, Rosenbach M, Kovarik C, Desai SR, et al. (October 2020). "The spectrum of COVID-19-associated dermatologic manifestations: An international registry of 716 patients from 31 countries". Journal of the American Academy of Dermatology (in English). 83 (4): 1118–1129. doi:10.1016/j.jaad.2020.06.1016. PMID 32622888.CS1 maint: unrecognized language (link)
  2. ↑ "COVID-19 dermatology registry" (in Turanci). American Academy of Dermatology. Retrieved 1 March 2021.
  3. ↑ Freeman EE, McMahon DE, Hruza GJ, Irvine AD, Spuls PI, Smith CH, et al. (September 2020). "International collaboration and rapid harmonization across dermatologic COVID-19 registries". Journal of the American Academy of Dermatology (in English). 83 (3): e261–e266. doi:10.1016/j.jaad.2020.06.050. PMID 32562840.CS1 maint: unrecognized language (link)
  4. ↑ 4.0 4.1 4.2 4.3 4.4 Genovese G, Moltrasio C, Berti E, Marzano AV (2021). "Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives". review. Dermatology (in english). 237 (1): 1–12. doi:10.1159/000512932. PMID 33232965.CS1 maint: unrecognized language (link)
  5. ↑ Feldman SR, Freeman EE (June 2021). Callen J, Duffin KC, Ofori AO, Corona R (eds.). "COVID-19: Cutaneous manifestations and issues related to dermatologic care". UpToDate. Wolters Kluwer. Retrieved 1 March 2021.
  6. ↑ 6.0 6.1 Shams S, Rathore SS, Anvekar P, Sondhi M, Kancherla N, Tousif S, et al. (March 2021). "Maculopapular skin eruptions associated with Covid-19: A systematic review". review. Dermatologic Therapy. 34 (2): e14788. doi:10.1111/dth.14788. PMC 7995033. PMID 33481314.
  7. ↑ Kaya G, Kaya A, Saurat JH (June 2020). "Clinical and Histopathological Features and Potential Pathological Mechanisms of Skin Lesions in COVID-19: Review of the Literature". review. Dermatopathology. Basel, Switzerland. 7 (1): 3–16. doi:10.3390/dermatopathology7010002. PMC 7583593. PMID 32608380.